Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

Abstract: Featured compounds have high monoamine transport affinity and are characterized by one of the following two general formulas set out above. The compounds bind selectively or non-selectively to monoamine transporters. The compounds are useful to treat various medical indications including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking cessation, weight reduction, obsessive-compulsive disorder, various forms of depression, traumatic brain injury, stroke, and narcolepsy.

Abstract: The use of various novel oxime ethers are described as fragrance chemicals. These chemicals are suitable for use in creating fragrance, and scents in items such as perfumes, colognes and personal care products is disclosed.

Abstract: A polymer having a crosslinked structure made from a polyol and an isocyanate where the crosslinks contain urethane and/or ester bonds made from the reaction of a benzylic hydroxyl group and an isocyanate group.

Abstract: The present invention provides a fragrance precursor of formula I: that is capable of forming a fragrant ketone of formula II: and a fragrant lactone of formula III:

Abstract: Provided are spirobifluorene compounds which can provide excellent processibility with improved solubility in organic solvents, an electroluminescence (EL) polymer obtained therefrom and an EL element having the same. The EL polymer comprising repeating units of the following formula: wherein R1 and R2 are identical or different and are independently a straight-chain or branched alkyl group having from 1 to 22 carbon atoms or an aryl group substituted by C1-C22 alkyl, and at least one of the R1 and R2 contains one or more atoms selected from the group consisting of O, N, S, Si and Ge.

Abstract: The use of various oxime ethers are described as fragrance chemicals, suitable for use in creating fragrance, and scents in items such as perfumes, colognes and personal care products is disclosed. Novel compounds are also disclosed.

Abstract: Optical systems such as, for example, optical switches, are disclosed comprising a solid component and a refractive index-matching liquid composition interfaced with the solid component. The liquid composition has a refractive-index that is substantially equal to that of the solid component. In one approach the liquid composition is a saturated cyclic compound consisting essentially of carbon and hydrogen and optionally oxygen such as, e.g., cyclic alkanes, alcohols or ketones. In another approach the liquid composition is benzene substituted with one or more electron-donating groups attached directly to the ring and one of more fluoro groups attached to the ring or to the electron-donating groups. In yet another approach the liquid composition is a combination comprising one or more of benzene or substituted benzene and optionally at least one of an alkane or substituted alkane having a boiling point less than about 130° C.

Abstract: The invention is directed to polymerizable vinyl compounds having halogenated aromatic groups and to a method of synthesizing such compounds. In particular, the invention is directed to polymerizable aromatic vinyl compounds wherein, except for the vinylic hydrogen atoms, aromatic C—H bonds are replaced by C—X bonds, where X is a halogen or other selected substituent having a de minimus number, if any, of C—H bonds; for example, without limitation, highly fluorinated fluoroalkanes. In addition, the compounds of the invention have a de minimus number, if any, of N—H and O—H bonds.

Abstract: The present invention relates to a process for preparing mixed substituted alkynyl ethers. More particularly, the invention concerns the preparation of mixed ethers derived from a benzyl type alcohol and a substituted alkynyl alcohol. The process of the invention for preparing a benzyl/substituted alkynyl type mixed ether is prepared from a benzyl/alkynyl type mixed ether with a hydrogen atom on the triple bond is characterized in that it consists of reacting a mixed ether derived from a benzyl type alcohol and an alkynyl alcohol with a hydrogen atom on the triple bond with an alkylation agent, in the presence of an anionisation agent.

Abstract: Compounds which mimic the chemical and/or biological activity of discodermolide are provided and intermediates useful in their preparation.

Abstract: The present invention provides a convergent method for the synthesis of ubiquinones and ubiquinone analogues. Also provided are precursors of ubiquinones and their analogues that are useful in the methods of the invention.

Abstract: The present invention provides a method for the synthesis of an A-ring synthon phosphine oxide used in the preparation of 19-nor vitamin D compounds, and to novel synthetic intermediates formed during the synthesis. The new method prepares the phosphine oxide from (D)-glucose.

Abstract: The invention aims at providing a process by which ethene derivatives of enol form represented by the general formula (I) can be obtained in high yield with the configuration of enolic double bond being retained: (I) wherein E is C(═X)R4, S(O)nR4, P(═X)R4R5, or the like and which comprises reacting a compound represented by the general formula (II): (II) with a compound represented by the general formula (III): EY . . . (III) wherein E is as defined above; and Y is chloro, bromo, or CN in the presence of a base and a pyridine derivative represented by the general formula (IV): (IV) wherein R6 is alkyl or the like.

Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

Abstract: A process for preparing toluene derivatives of the formula I 1

Abstract: The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.

Abstract: The present invention provides a process for producing an alkanediol derivative represented by the general formula (II) from an ester compound represented by the general formula (I), safely without giving rise to racemization. The present invention lies in a process for producing an alcohol derivative represented by the following general formula (II): (wherein R2 and R3 are each independently a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; X is a hydrogen atom or a protecting group for hydroxyl group; and n is 0 or 1), which process comprises reducing an ester compound represented by the following general formula (I): (wherein R1 is an alkyl group having 1 to 4 carbon atoms; and R2, R3, X and n have the same definitions as given above) with sodium borohydride in a mixed solvent of at least one kind of solvent selected from the group consisting of aromatic hydrocarbons, aliphatic hydrocarbons and alicyclic hydrocarbons and a primary alcohol.

Abstract: The use of various novel oxime ethers are described as fragrance chemicals. These chemicals are suitable for use in creating fragrance, and scents in items such as perfumes, colognes and personal care products is disclosed.

Abstract: The use of various oxime ethers are described as fragrance chemicals, suitable for use in creating fragrance, and scents in items such as perfumes, colognes and personal care products is disclosed. Novel compounds are also disclosed.

Abstract: The present invention provides a method for the synthesis of an A-ring synthon phosphine oxide used in the preparation of 19-nor vitamin D compounds, and to novel synthetic intermediates formed during the synthesis. The new method prepares the phosphine oxide from (D)-glucose.

Abstract: The invention concerns a method for preparing a benzylic-type ether from an aromatic compound. The inventive method for preparing a benzylic-type ether from an aromatic compound is characterised in that it consists in: in a first step, acylating an aromatic compound by reacting said aromatic compound with an acylating agent, in the presence of an efficient amount of zeolite or a Friedel-Crafts catalyst leading to a ketonic compound; in a second step, reducing the carbonyl group into carbinol leading to a benzylic alcohol; in a third step, etherifying the hydroxyl group, by reacting the benzylic alcohol with another alcohol, in the presence of an efficient amount of zeolite.

Abstract: Process for the telomerization of a conjugated diene,

Abstract: A palladium catalyzed cross-coupling of aryldiazonium salts with organosilanes is disclosed. New reactions that are user friendly and environmentally friendly are now possible, including some reactions that could not be achieved using prior methods. The organosilanes that may be cross-coupled with aryldiazonium salts include, for example, Ar′—Si(L)3, where Ar′=aryl, and where L=CH3, OCH3, F, Cl, R, or OR.

Abstract: The invention relates to a process for the synthesis of aryl alkyl monoethers by reaction of a phenol compound, comprising one or more hydroxyl groups attached to the aromatic system, and of a dialkyl carbonate. It is a solvent-free process carried out at a pressure of between 0.93×105 Pa and 1.07×105 Pa, at a temperature of between 100° C. and 200° C., and in the presence of a catalyst chosen from the group consisting of alkaline carbonates and alkaline hydroxides. The dialkyl carbonate is added gradually to the reaction mixture.

Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

Abstract: The present invention provides a method for alkoxylating organic compounds comprising contacting an organic compound adapted to be alkoxylated with an alkylene oxide in a reaction vessel under conditions effective to alkoxylate the organic compound. The alkylene oxide is maintained in vapor form during transport to said reaction vessel, during discharge into said reaction vessel, and during contacting of the organic compound with the alkylene oxide. The result is an alkoxylated product containing less flocculant.

Abstract: Compounds are used as catalysts according to general formula (1) M+x(C(SO2CF3)3)x, whereby x is equal to 1 or 2; M represents one hydrogen or alkaline metal atom when x equals 1; and M represents one alkaline-earth metal atom when x equals 2. The invention also relates to a novel Mg compound of formula (1).

Abstract: The polymerizable compound of this invention is represented by general formula (I): where R is H, R′, R′O, R′COO, or R′OCO, R′ is a linear or branched alkyl group or alkenyl group having 1 to about 15 carbon atoms, A1 and A2 are independently a cyclohexane ring or a benzene ring which may include a substituent represented by formula (II) below; X is H or CH3; and Y1, Y2, Y3, and Y4 are independently H, F, Cl, CH3, CH3O, CF3, or CF3O wherein at least two of Y1, Y2, Y3, and Y4 are H and, if both A1 and A2 are cyclohexane rings, at least one of Y1, Y2, Y3, and Y4 is not H: where Y5, Y6, Y7, and Y8 are independently H, F, Cl, CH3, CH3O, CF3, or CF3O, at least two of Y5, Y6, Y7, and Y8 are H.

Abstract: Indane dimer compounds of general formula 5, 6 or 9 and their pharmaceutical use, particularly to achieve smooth muscle relaxing activity and/or mast cell stabilizing activity and/or antiinflammatory activity are described, wherein in formulae 5 and 9, R1 and R3 to R15, and in formula 6, R1, R2 and R4 to R15, are selected from one or more of the same or different of: H, halo, hydroxy, alkoxy, aryloxy, acetoxy, carboxy, alkyl carbonyl, hydro carbonyl, amino, amido, alkylamino, hydroxylamino, amine oxide groups, azo groups, cyano, hydrazino groups, hydrazide groups, hydrazone groups, imide groups, iminoether groups, ureyl groups, oximc, nitro, nitrate, nitrite, nitroso groups, nitrile, heterocyclic groups containing one or more heteroatoms selected from N, O or S, aralkyl groups, mono and polybenzoid aryl groups, substituted aryl groups, thiol, thioureyl, phenylthiol groups, sulphonic acid groups, sulphoxide groups, sulphone groups, alkyl containing 1 to 10 carbon atoms or cycloalkyl groups containing 3 to 8 ca

Abstract: The invention provides a novel compound 4-(p-methoxy-phenyl)-2-aminobutane exhibiting growth inhibition and antifeedant activity and represented by the structural formula.

Abstract: 3-Substituted benzotrifluorides are selectively deprotonated and functionalized in the 2-position. The selectivity is achieved by equilibrating the mixture of lithiobenzotrifluorides initially formed in the presence of a primary or secondary amine catalyst.

Abstract: Omega chain modified 15-HETE derivatives and methods of their use for treating dry eye are disclosed.

Abstract: The invention relates to a method for producing a novel optically active compound represented by the general formula [IV]. This method includes the step of reacting a vinyl ether with a halogenated acetaldehyde in the presence of an optically active binaphthol-titanium complex. With this, the novel optically active compound can be produced very easily. Furthermore, the novel optically active compound can easily be oxidized to a novel optically active &agr;,&bgr;-dihydrexyketone represented by the general formula [V]. These novel optically active compounds can each be used as useful intermediates.

Abstract: The present invention is a novel process, with or without solvent, for manufacture of compounds of the formula wherein P is selected from phenyl and naphthyl; wherein R1 and R2 and R3 are each independently selected from hydrogen, alkyl, alkoxy, aryl, aralkyl, aralkoxy, halogen, alkoxyalkoxy, and aralkoxyalkoxy; wherein R5 is selected from substituted or unsubstituted phenyl, and substituted or unsubstituted naphthyl, the substituents being each independently selected from alkyl (C1-C8), alkoxy (C1-C8), aroxy, aralkoxy (C1-C8) and halogen.

Abstract: The subject matter of the invention is the process for the preparation of mixed ethers of formula I, wherein Ar represents an aromatic or one or more heteroatom-containing moiety, optionally substituted by one or more C1-4 alkoxy, methylenedioxy, C1-4 alkyl, halogen, C1-4 haloalkyl or nitro-group, and/or condensed with a benzene ring; R1 and R2 independently mean hydrogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, phenyl, substituted phenyl, C3-6 cycloalkyl group, R3 means C3-6 alkynyl, optionally substituted by one or more C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C1-6 haloalkyl group, or halogen atom, R3 also means a C1-4 alkyloxy-C1-4 alkyloxy-C1-4 alkyl group.

Abstract: Process for the coupling of

Abstract: Compounds of general formula (1): 1

Abstract: An improved process for the preparation of 2-arylvinyl alkyl ether compounds of the structural formula I In addition, the present invention provides an improved process for the preparation of 1,4-diaryl-2-fluoro-2-butene compounds of the structural formula V

Abstract: A process for the selective enzymatic hydroxylation of aldehydes and ketones using chiral anchor-protective groups.

Abstract: A process for producing trifluoroethoxybenzoic acids or salts thereof by reaction of halobenzoic acids or salts thereof with 2,2,2-trifluoroethanol in the presence of a strong base and copper containing materials. The compounds obtained by the process of the present invention may be used as synthetic intermediates in the pharmaceutical industry.

Abstract: The present invention provides a method, compounds, and compositions for treating a disease associated with immune dysfunction. In accordance with the method, a pharmacologically-acceptable composition including at least one compound selected from the group of compounds consisting of 5-alkyl-resorcinol derivatives, cannabinol derivatives, cannabidiol derivatives, cannabigerol derivatives, and combinations thereof is administered to a patient under conditions sufficient to attenuate the dysfunction within the immune system. The invention also provides an antiviral cannabinol derivative that can be used in the inventive method. The invention also provides an alkylated resorcinol derivative and a method of using the alkylated resorcinol derivative to attenuate the growth of a neoplasm. The method and compound are useful for treating diseases of the immune system, such as HIV disease and neoplastic disorders.

Abstract: A process for preparing tetrahydrofuran, which comprises reacting 1,4-butenediol diethers of the formulae I and/or II RO—CH2—CH═CH—CH2—OR  I RO—CH2—CH2═CH—CH2—OR  II, where the R radicals can be identical or different and are C1-C15-alkyl or cycloalkyl radicals, C6-C12-aryl radicals or C7-C15-aralkyl radicals, with water and hydrogen at from 20 to 300° C. under from 1 to 300 bar in the presence of catalysts or catalyst combinations which comprise components which are both capable of hydrogenation and have acidic or basic centers and a novel process for preparing 1,4-butanediol diethers of the formula I by metathesis are described.

Abstract: Synthetic methods for lactone-containing compounds such as the discodermolides are provided, as are compounds which mimic the chemical and/or biological activity thereof, and methods and intermediates useful in their preparation.

Abstract: There is described a four step process for the production of halogeno-o-hydroxydiphenyl compounds having the formula in which X is —O—or —CH2—; m is 1 to 3; and n is 1 or 2; wherein in the first step, a diphenyl compound is chlorinated; in a second step the chlorinated compound is acylated in a Friedel-Crafts reaction and optionally again chlorinated after the acylation; in a third step the acyl compound is oxidised; and in a fourth step the oxidized compound is hydrolyzed. The compounds of formula (1) are useful for the protection of organic materials against microorganisms.

Abstract: Liquid crystalline compounds are provided which have an extremely high voltage holding ratio, altered only slightly by change of temperature, and which have a low threshold voltage and a high &Dgr;n. Also provided are liquid crystal compositions containing the liquid crystalline compound; and liquid crystal display devices containing the liquid crystal composition. The liquid crystalline compound is expressed by the general formula (1) wherein R, Y1 to Y16, X and Z1 to Z3 are defined in claim 1.

Abstract: A liquid crystalline compound represented by the general formula (1) ##STR1## wherein R.sub.1 represents an alkyl or alkoxy group having 1 to 10 carbon atoms, a cyano group, a halogen atom, or an alkyl or alkoxy halide group having 1 to 4 carbon atoms; R.sub.2 represents an alkyl group having 1 to 10 carbon atoms; rings A.sub.1, A.sub.2, A.sub.3, and A.sub.4 each independently represent a 1,4-phenylene or 1,4-cyclohexylene group; Z.sub.1, Z.sub.2, and Z.sub.3 each independently represent a covalint bond, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C-- or --COO--; 1 and m are 0 pr 1; and n is 0 to 10.

Abstract: This invention provides LC compositions useful as birefringent materials in electrooptic devices which exhibit zero or low negatively sloped birefringence dispersion (e.g., exhibiting positive birefringence dispersion significantly lower than that of currently available LC compositions) or more preferably positively sloped birefringence dispersion in which birefringence of the material increases with wavelength. The invention provides compounds useful as components of LC compositions which exhibit negative birefringence where n.sub.o is higher than n.sub.e. The compounds of this invention are dimers of LC-like compounds in which the monomers are linked to each other through a high birefringence moiety (dimerization linker). The LC monomers consist of an LC core and one or two tail groups. Preferred monomers for this invention have low birefringence in comparison to the birefrigence of the monomer linking moiety.

Abstract: A preparation process of phenol aralkyl resin from phenol compound and aralkyl compound by controlling the temperature of reaction mass in the range of 70 to 240.degree. C. and simultaneously controlling the temperature of vapor phase potion and vapor-liquid interface portion of manufacturing equipment so as to keep the wall surface of the vapor phase portion and vapor-liquid interface portion in a wet state. The invention can prevent scale adhesion to the interior of manufacturing equipment, remarkably reduce the number of washing and scale removing procedures on the manufacturing equipment, and enable efficient manufacture of phenol aralkyl resin. When the phenol aralkyl resin obtained is used for a molding material, molded articles having excellent heat resistance and high reliability can be provided.

Abstract: Novel pharmaceutically/cosmetically-active aromatic polyenic compounds have the structural formula (I): and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.